Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum
October 13 2016 - 7:01AM
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, today announced that Ramesh Kumar,
Ph.D., President and Chief Executive Officer, will present a
company update at the 2016 BIO Investor Forum being held at the
Westin St. Francis Hotel in San Francisco, CA. The
presentation will take place on Wednesday, October 19th at 10:30 AM
PT.
A live webcast of the presentation will be
available at this link or can be accessed by visiting "Events &
Presentations" in the Investors and Media section of the Company's
website at www.onconova.com. An archived replay of the webcast
will be available on the Company's website after the
conference.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a Phase 3
clinical-stage biopharmaceutical company focused on discovering and
developing novel products to treat cancer. Onconova's
clinical and pre-clinical stage drug development candidates are
derived from its extensive chemical library and are designed to
work against specific cellular pathways that are important in
cancer cells, while causing minimal damage to normal cells. The
Company’s most advanced product candidate, rigosertib, is a small
molecule inhibitor of cellular signaling and acts as a RAS mimetic.
These effects of rigosertib appear to be mediated by direct binding
of the compound to the RAS-binding domain (RBD) found in many RAS
effector proteins, including the Raf kinases and PI3K.
Rigosertib is protected by issued patents (earliest expiry in 2026)
and has been awarded Orphan Designation for MDS in the United
States, Europe and Japan. In addition to rigosertib, two
other candidates are clinical stage, and several candidates are in
pre-clinical stages. For more information, please
visit http://www.onconova.com.
Forward Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements relate to future events or Onconova
Therapeutics, Inc.'s future operations, clinical development of
Onconova's product candidates and presentation of data with respect
thereto, regulatory approvals, expectations regarding the
sufficiency of Onconova's cash and other resources to fund
operating expenses and capital expenditures, Onconova's anticipated
milestones and future expectations and plans and prospects.
Although Onconova believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Onconova has attempted to identify forward-looking statements by
terminology including “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “should,”
“approximately” or other words that convey uncertainty of future
events or outcomes. These statements are only predictions and
involve known and unknown risks, uncertainties, and other factors,
including Onconova’s need for additional financing and current
plans and future needs to scale back operations if adequate
financing is not obtained, the success and timing of Onconova’s
clinical trials and regulatory approval of protocols, and those
discussed under the heading “Risk Factors” in Onconova’s most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q.
Any forward-looking statements contained in this
release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
CONTACT: Onconova Therapeutics
Benjamin Hoffman, 267-759-3036
bhoffman@onconova.us
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024